drugset / Trial / NCT01203514

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

This study tested the safety and efficacy of transfusing erythropoietin (Epo) and iron in infants of \<1,250g birth weight. For infants 401-1,000g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the number of transfusions received. For infants 1,001-1,250g birth weight, we tested whether early erythropoietin (Epo) and iron therapy would decrease the percentage of infants who received any transfusions.

Timeline

Start
1997-08
Primary completion
1998-08
Completion
2000-08

Outcome

Missed primary endpoint

paper Treated and placebo/control infants in trial 1 received a similar number of transfusions (4.3 +/- 3.6 vs 5.2 +/- 4.2, respectively). PMID 11581447 ↗

paper A similar percentage of treated and control infants in trial 2 received at least 1 transfusion (37% vs 46%). PMID 11581447 ↗

paper However, the lack of impact on transfusion requirements fails to support routine use of early Epo. PMID 11581447 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 400 iu/kg —
Background Iron dextran Unknown 5 mg/kg Intravenous